```html

Adenocarcinoma of the Lung

This guide provides an evidence‑based overview of lung adenocarcinoma, the most common type of non‑small cell lung cancer (NSCLC). Information is presented in plain language for patients and caregivers, with references to reputable medical sources.

Overview

What it is: Adenocarcinoma of the lung is a malignant tumor that arises from glandular (secretory) cells in the lung’s outer regions, known as the peripheral lung tissue. It belongs to the non‑small cell lung cancer (NSCLC) family, which accounts for about 85% of all lung cancers.

Who it affects: Historically considered a disease of smokers, adenocarcinoma now occurs in both smokers and never‑smokers. It is slightly more common in women than men and tends to be diagnosed at a younger age than other NSCLC subtypes.

Prevalence: In the United States, adenocarcinoma represents roughly 40% of all lung cancers, translating to over 115,000 new cases each year [1, CDC Cancer Facts & Figures, 2023]. Globally, lung cancer is the leading cause of cancer death, with adenocarcinoma being the dominant histology in many regions, especially East Asia.

Symptoms

Early-stage adenocarcinoma often causes no symptoms, which is why screening is important for high‑risk individuals. When symptoms appear, they may be vague and develop gradually.

• Persistent cough – New or worsening cough that doesn’t improve with usual remedies.
• Chest pain – A dull, aching discomfort that may worsen with deep breathing or coughing.
• Shortness of breath (dyspnea) – Feeling winded during activities that were previously easy.
• Wheezing – A high‑pitched whistling sound during exhalation.
• Hemoptysis – Coughing up blood or rust‑colored sputum.
• Unexplained weight loss – Losing more than 5% of body weight without trying.
• Fatigue – Persistent tiredness that interferes with daily activities.
• Recurrent respiratory infections – Frequent bronchitis or pneumonia.
• Hoarseness – Changes in voice due to involvement of the recurrent laryngeal nerve.
• Swelling in the face or neck – May indicate superior vena cava syndrome (a medical emergency).

Because many of these signs overlap with benign conditions (e.g., asthma, COPD), any new or persistent respiratory symptom should prompt a discussion with a healthcare professional.

Causes and Risk Factors

While the exact cause of any single cancer case is rarely known, several factors increase the likelihood of developing lung adenocarcinoma.

Environmental and Lifestyle Factors

• Tobacco smoke – Even low‑intensity or former smoking raises risk; the relative risk is ~2‑3‑fold for adenocarcinoma [2, WHO Tobacco Report, 2021].
• Secondhand smoke – Non‑smokers regularly exposed to smoke have a 20‑30% higher risk.
• Radon exposure – The leading cause of lung cancer among never‑smokers; indoor radon can be measured with a cheap test kit.
• Occupational carcinogens – Asbestos, silica, diesel exhaust, and certain metals (e.g., nickel, chromium) increase risk.
• Air pollution – Fine particulate matter (PM2.5) is linked to a modest but significant rise in lung cancer incidence.

Genetic and Biological Factors

• Genetic mutations – EGFR, KRAS, ALK, ROS1, and BRAF alterations are common driver mutations in adenocarcinoma and can be inherited or acquired.
• Family history – Having a first‑degree relative with lung cancer modestly raises risk.
• Gender – Women, especially never‑smoking Asian women, have a higher prevalence of EGFR‑mutated adenocarcinoma.
• Age – Incidence increases sharply after age 55, but cases are reported in patients as young as 30.

Other Risk Modifiers

• Previous lung disease (e.g., COPD, pulmonary fibrosis)
• Immunosuppression (e.g., HIV, organ transplant)
• History of radiation therapy to the chest

Diagnosis

Diagnosing lung adenocarcinoma requires a combination of imaging, tissue sampling, and molecular testing.

Imaging Studies

• Chest X‑ray – Often the first test; can reveal a peripheral nodule or mass.
• Low‑dose CT (computed tomography) scan – Recommended for screening high‑risk adults (age 50‑80 with a 20 pack‑year smoking history, now former smokers who quit ≤15 years ago) [3, USPSTF Recommendation, 2022]. Detects nodules <5 mm in size.
• Contrast‑enhanced CT – Assesses size, borders, involvement of mediastinal structures, and helps guide biopsies.
• Positron emission tomography (PET)‑CT – Highlights metabolically active tissue, useful for staging and detecting distant spread.
• MRI – Preferred for evaluating brain metastases.

Biopsy & Pathology

• Bronchoscopy with transbronchial biopsy – Useful for central lesions.
• CT‑guided percutaneous needle biopsy – Ideal for peripheral nodules typical of adenocarcinoma.
• Surgical biopsy (lobectomy or wedge resection) – Provides the most tissue for definitive diagnosis.
• Pathology – Tumor cells are examined under a microscope; adenocarcinoma shows glandular formation or mucin production.

Molecular and Genetic Testing

Guidelines recommend routine testing for EGFR, ALK, ROS1, BRAF, KRAS, and PD‑L1 expression on all newly diagnosed NSCLC specimens. Results direct targeted therapy and immunotherapy decisions [4, NCCN Guidelines, 2023].

Staging

The TNM system (Tumor size, Node involvement, Metastasis) stages disease from I (localized) to IV (advanced). Accurate staging determines treatment intent (curative vs. palliative).

Treatment Options

Treatment is individualized based on stage, molecular profile, patient health, and preferences. Multidisciplinary care (oncology, thoracic surgery, radiation, pulmonology, palliative care) yields the best outcomes.

Localized Disease (Stage I‑II)

• Surgery – Lobectomy (removal of an entire lobe) is the standard curative approach; segmentectomy may be considered for small (<2 cm) tumors.
• Adjuvant chemotherapy – Typically a platinum‑based doublet (cisplatin + pemetrexed) for stage II or high‑risk stage I.
• Targeted adjuvant therapy – EGFR‑mutated tumors may receive osimertinib for up to 3 years post‑surgery (ADAURA trial) [5, NEJM, 2020].
• Radiation – Post‑operative (PORT) radiation is reserved for patients with positive surgical margins or N2 nodal disease.

Locally Advanced Disease (Stage III)

• Concurrent chemoradiation – Platinum‑based chemotherapy combined with 60‑66 Gy thoracic radiation.
• Immunotherapy consolidation – Durvalumab for up to 12 months after chemoradiation improves overall survival (PACIFIC trial) [6, Lancet Oncology, 2018].
• Surgery – In select cases (III‑A), multimodality therapy including resection may be offered.

Metastatic Disease (Stage IV)

• Targeted therapy – Depends on driver mutation:
  • EGFR: osimertinib, erlotinib, gefitinib, afatinib
  • ALK: alectinib, brigatinib, lorlatinib
  • ROS1: entrectinib, crizotinib
  • BRAF V600E: dabrafenib + trametinib
• Immunotherapy – PD‑1/PD‑L1 inhibitors (pembrolizumab, atezolizumab, nivolumab) alone or combined with chemotherapy for tumors without targetable mutations.
• Chemotherapy – Platinum + pemetrexed is the backbone for non‑targeted, non‑PD‑L1‑high disease.
• Palliative radiation – For symptomatic brain, bone, or chest lesions.
• Supportive care – Oxygen, pain control, nutritional support, and psychosocial services.

Lifestyle & Supportive Measures

• Smoking cessation – Improves response to treatment and reduces secondary cancers.
• Exercise – Light to moderate activity (e.g., walking 30 min most days) can preserve muscle mass and reduce fatigue.
• Nutrition – High‑protein, calorie‑dense meals help maintain weight; consider consulting a dietitian.
• Vaccinations – Annual flu vaccine and COVID‑19 booster reduce infection risk during immunosuppressive therapy.

Living with Adenocarcinoma of the Lung

Managing life after diagnosis involves medical follow‑up and daily self‑care strategies.

Follow‑up Schedule

• Every 3‑6 months for the first 2 years (history, physical exam, CT chest)
• Every 6‑12 months thereafter up to 5 years
• Additional imaging (PET, MRI) if new symptoms arise.

Symptom Management

• Cough – Humidified air, honey‑lemon drinks, or low‑dose opioids for severe cough.
• Dyspnea – Pulmonary rehabilitation, supplemental oxygen, and breathing exercises.
• Pain – WHO analgesic ladder; consider nerve blocks for chest wall pain.
• Fatigue – Energy‑conservation techniques, scheduled rest, and treatment of anemia if present.
• Emotional health – Join support groups, counseling, or mindfulness programs.

Practical Tips

• Keep a symptom diary to share with your care team.
• Carry a list of current medications (including over‑the‑counter) and allergies.
• Plan transportation ahead for radiation or infusion appointments.
• Use a medical alert bracelet indicating “lung cancer – on targeted therapy” if you are on oral TKIs.
• Discuss fertility, contraception, and family planning early if of child‑bearing age.

Prevention

While you cannot change your genetic makeup, many modifiable factors can lower your risk:

• Never start smoking – The single most effective preventive step.
• Quit smoking – Risk drops by ~50% after 10 years of abstinence.
• Test homes for radon – Mitigate high radon levels (>148 Bq/m³) with ventilation or sealing.
• Reduce occupational exposures – Use protective equipment and follow safety regulations.
• Maintain a healthy lifestyle – Regular exercise, balanced diet rich in fruits/vegetables, and maintaining a healthy weight.
• Vaccination – HPV vaccine indirectly reduces lung cancer risk linked to certain viral infections.

Complications

If left untreated or inadequately managed, adenocarcinoma can lead to serious complications:

• Airway obstruction – Causes atelectasis, severe dyspnea, and recurrent infections.
• Pleural effusion – Fluid accumulation that can compress the lung.
• Superior vena cava (SVC) syndrome – Facial swelling, neck vein distension, and headache; requires urgent treatment.
• Metastatic spread – Common sites: brain, bones, liver, adrenal glands.
• Paraneoplastic syndromes – Ectopic hormone production causing hypercalcemia, hyponatremia, or clotting disorders.
• Treatment‑related toxicities – Myelosuppression, pneumonitis (from radiation or immunotherapy), cardiac effects from certain TKIs.

When to Seek Emergency Care

---

References

1. Centers for Disease Control and Prevention. Lung Cancer Statistics. Updated 2023.
2. World Health Organization. Tobacco and Its Environmental Impact. 2021.
3. U.S. Preventive Services Task Force. Lung Cancer Screening. Recommendation Statement, 2022.
4. National Comprehensive Cancer Network. NCCN Guidelines for NSCLC. Version 8.2023.
5. Wu YL et al. Osimertinib in Resected EGFR‑Mutated NSCLC (ADAURA). New England Journal of Medicine. 2020;383:1711‑1723.
6. Antonia SJ et al. Durvalumab after Chemoradiotherapy in Stage III NSCLC (PACIFIC). Lancet Oncology. 2018;19:347‑357.

```